Page 5 - Nasdaq Xfor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq xfor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Xfor Today - Breaking & Trending Today

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Buy" from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have issued a report on the […] ....

Piper Sandler , Adams Mostafa , Securities Exchange Commission , Pharmaceuticals Daily , Morgan Stanley , Millennium Management , Geode Capital Management , Jpmorgan Chase Co , Cantor Fitzgerald , Schonfeld Strategic Advisors , Pharmaceuticals Inc , Pharmaceuticals Price Performance , Get Rating , Marketbeat Ratings , Exchange Commission , Strategic Advisors , Capital Management , X4 Pharmaceuticals , Nasdaq Xfor ,

Brokers Issue Forecasts for X4 Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Stock analysts at HC Wainwright boosted their Q1 2023 EPS estimates for X4 Pharmaceuticals in a research report issued on Wednesday, March 22nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.21) for the quarter, up from their previous […] ....

Adams Mostafa , Piper Sandler , Pharmaceuticals Daily , Bain Capital Life Sciences Investors , Pharmaceuticals Stock Performance , Cantor Fitzgerald , Vanguard Group Inc , Management Company , Pharmaceuticals Inc , Get Rating , Capital Life Sciences Investors , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates , Hc Wainwright ,

X4 Pharmaceuticals (NASDAQ:XFOR) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) in a research report report published on Wednesday, Benzinga reports. Cantor Fitzgerald currently has a $3.00 price objective on the stock. Cantor Fitzgerald also issued estimates for X4 Pharmaceuticals’ FY2023 earnings at ($1.06) EPS. A number of other equities analysts […] ....

Adams Mostafa , Piper Sandler , Pharmaceuticals Daily , Securities Exchange Commission , Cantor Fitzgerald , Schonfeld Strategic Advisors , Geode Capital Management , Pharmaceuticals Inc , Millennium Management , Morgan Stanley , Pharmaceuticals Price Performance , Pharmaceuticals Company Profile , Jpmorgan Chase Co , Get Rating , Exchange Commission , Strategic Advisors , Capital Management , X4 Pharmaceuticals , Nasdaq Xfor , Reiterated Rating ,

Cantor Fitzgerald Weighs in on X4 Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Equities researchers at Cantor Fitzgerald reduced their FY2023 earnings per share estimates for X4 Pharmaceuticals in a research note issued on Wednesday, March 22nd. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($1.06) per share for the year, down from their […] ....

Piper Sandler , Adams Mostafa , Morgan Stanley , Pharmaceuticals Inc , Lexaurum Advisors , Connor Clark Lunn Investment Management Ltd , Pharmaceuticals Stock Performance , Virtu Financial , Securities Exchange Commission , Pharmaceuticals Company Profile , Cantor Fitzgerald , Pharmaceuticals Daily , Get Rating , Aurum Advisors , Lunn Investment Management , Street Group , Exchange Commission , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates ,

X4 Pharmaceuticals (NASDAQ:XFOR) PT Lowered to $3.00 at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price objective lowered by HC Wainwright from $5.00 to $3.00 in a report released on Wednesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q1 2023 earnings at ($0.21) EPS, Q2 2023 earnings […] ....

Piper Sandler , Adams Mostafa , Pharmaceuticals Daily , Bain Capital Life Sciences Investors , Pharmaceuticals Price Performance , Pharmaceuticals Company Profile , Management Company , Securities Exchange Commission , Cantor Fitzgerald , Vanguard Group Inc , Pharmaceuticals Inc , Get Rating , Exchange Commission , Capital Life Sciences Investors , X4 Pharmaceuticals , Nasdaq Xfor , Lower Price Target , Hc Wainwright ,